Preferred Label : Nivolumab;
MeSH definition : A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that
binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used
as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant
MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL
LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA.;
MeSH hyponym : ONO 4538; ONO4538; MDX 1106; MDX1106; BMS 936558; BMS936558;
UNII : 31YO63LBSN;
Origin ID : D000077594;
UMLS CUI : C3657270;
- ATC code(s)
- Allowable qualifiers
- Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- Pharmacological action(s)
- Record concept(s)
- See also (suggested by CISMeF)
- Semantic type(s)
- Validated automatic mappings to BTNT
A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that
binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used
as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant
MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL
LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA.
https://ansm.sante.fr/tableau-atu-rtu/opdivo-nivolumab-solution-a-diluer-pour-perfusion-yervoy-ipilimumab-solution-a-diluer-pour-perfusion
2024
false
false
false
France
French
guidelines for drug use
Nivolumab
Ipilimumab/Nivolumab Regimen
Ipilimumab
Antineoplastic Agents, Immunological
Malignant Pleural Mesothelioma
disease progression
Progressive Neoplastic Disease
infusions, intravenous
continuity of patient care
drug monitoring
carcinoma, non-small-cell lung
melanoma
Stage IIB Cutaneous Melanoma AJCC v6 and v7
Stage IIIB Cutaneous Melanoma AJCC v7
technical report
---
https://www.has-sante.fr/jcms/p_3490820/fr/opdualag-nivolumab/relatlimab-melanome
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
drug combinations
relatlimab
nivolumab and relatlimab
Nivolumab
Antineoplastic Agents, Immunological
infusions, intravenous
Unresectable Cutaneous Melanoma
adult
adolescent
PD-L1 Expression Less than 1 Percent
Advanced Cutaneous Melanoma
evaluation of the transparency committee
melanoma
---
https://www.has-sante.fr/jcms/p_3527277/fr/opdivo-nivolumab-cancer-bronchique-cbnpc
2024
false
false
false
France
evaluation of the transparency committee
Nivolumab
cancer
Malignant Neoplasm
bronchus, nos
neoplasm, malignant
Bronchial
carcinoma, non-small-cell lung
Opdivo
nivolumab
Nivolumab
---
https://www.has-sante.fr/jcms/p_3417971/fr/opdivo-nivolumab-adenocarcinome-gastrique
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
Advanced Gastric Adenocarcinoma
Metastatic Gastric Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Advanced Gastroesophageal Junction Adenocarcinoma
adenocarcinoma of esophagus
esophageal neoplasms
Advanced Esophageal Adenocarcinoma
Metastatic Esophageal Adenocarcinoma
HER2/Neu Negative
PD-L1 Positive
infusions, intravenous
nivolumab
evaluation of the transparency committee
adenocarcinoma
Nivolumab
stomach neoplasms
---
https://www.has-sante.fr/jcms/p_3451663/fr/opdivo-nivolumab-melanome
2023
false
false
false
France
Nivolumab
melanoma
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3460521/fr/opdivo-nivolumab-cancer-bronchique-cbnpc
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
guidelines for drug use
nivolumab
infusions, intravenous
Antineoplastic Agents, Immunological
bronchial neoplasms
programmed cell death 1 receptor
antineoplastic combined chemotherapy protocols
PD-L1 Expression Greater than or Equal to 1 Percent
neoadjuvant therapy
adult
platinum compounds
Sensitizing EGFR Mutation Negative
ALK Gene Translocation Negative
evaluation of the transparency committee
Nivolumab
carcinoma, non-small-cell lung
---
https://www.has-sante.fr/jcms/p_3471682/fr/opdivo-nivolumab-cbnpc-cancer-bronchique-non-a-petites-cellules
2023
false
false
false
France
bronchial neoplasms
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
nivolumab
antineoplastic combined chemotherapy protocols
platinum compounds
neoadjuvant therapy
resectable non-small cell lung cancer at high risk of recurrence in patients whose
tumours have PD-L1 expression ≥ 1%
evaluation of the transparency committee
Nivolumab
carcinoma, non-small-cell lung
---
https://www.has-sante.fr/jcms/p_3382948/fr/opdivo-nivolumab-carcinome-urothelial-infiltrant-le-muscle-cuim
2022
false
false
false
France
French
treatment outcome
insurance, health, reimbursement
Nivolumab
nivolumab
carcinoma, transitional cell
urinary bladder neoplasms
PD-L1 Positive
evaluation of the transparency committee
adult
Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
infusions, intravenous
Antineoplastic Agents, Immunological
---
https://www.has-sante.fr/jcms/p_3359098/fr/opdivo-nivolumab-carcinome-urothelial
https://www.has-sante.fr/jcms/p_3359104/fr/decision-n2022-0246/dc/sem-du-13-juillet-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-opdivo
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
guidelines for drug use
infusions, intravenous
Antineoplastic Agents, Immunological
nivolumab
adult
Urothelial Carcinoma
evaluation of the transparency committee
Nivolumab
---
https://www.has-sante.fr/jcms/p_3334854/fr/opdivo-nivolumab-adenocarcinome-gastrique-de-la-jonction-oeso-gastrique-ou-de-l-oesophage
2022
false
false
false
France
French
evaluation of the transparency committee
adenocarcinoma of esophagus
traction
Nivolumab
Opdivo
adenocarcinoma
esophagospasm
Esophagus
esophagogastric junction
nivolumab
indication of
stomach, nos
adenocarcinoma of esophagus
indicators and reagents
Esophagus
indicators
Esophagus adenocarcinoma
junctional
---
https://www.has-sante.fr/jcms/p_3332767/fr/opdivo-nivolumab-carcinome-epidermoide-de-l-oesophage
2022
false
false
false
France
French
evaluation of the transparency committee
Esophagus squamous cell carcinoma
Nivolumab
esophagus
esophagospasm
registries
carcinoma, squamous cell
Esophagus
Opdivo
Esophagus
nivolumab
Esophageal Squamous Cell Carcinoma
---
https://www.ema.europa.eu/en/medicines/human/EPAR/opdualag
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
Relatlimab
Relatlimab
Nivolumab
Nivolumab
Antineoplastic Agents, Immunological
nivolumab and relatlimab
melanoma
product surveillance, postmarketing
Advanced Cutaneous Melanoma
Metastatic Cutaneous Melanoma
Unresectable Cutaneous Melanoma
adolescent
adult
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
PD-L1 Expression Less than 1 Percent
infusions, intravenous
programmed cell death 1 receptor
receptors, immunologic
Lag3 protein, human
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
relatlimab
relatlimab
---
https://www.has-sante.fr/jcms/p_3318372/fr/opdivo-nivolumab-adenocarcinome-gastrique
https://www.has-sante.fr/jcms/p_3318378/fr/decision-n-2022-0064/dc/sem-du-17-fevrier-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-opdivo
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
stomach neoplasms
esophageal neoplasms
antineoplastic agents
adult
antineoplastic combined chemotherapy protocols
esophagogastric junction
neoplasm metastasis
Metastatic Gastroesophageal Junction Adenocarcinoma
Advanced Gastroesophageal Junction Adenocarcinoma
Advanced Gastric Adenocarcinoma
Metastatic Gastric Adenocarcinoma
adenocarcinoma of esophagus
Advanced Esophageal Adenocarcinoma
Metastatic Esophageal Adenocarcinoma
infusions, intravenous
nivolumab
evaluation of the transparency committee
adenocarcinoma
Nivolumab
---
https://www.has-sante.fr/jcms/p_3308678/fr/opdivo/yervoy-nivolumab/ipilimumab-mesotheliome-pleural-malin
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
Unresectable Pleural Malignant Mesothelioma
Ipilimumab
Nivolumab
Ipilimumab/Nivolumab Regimen
survival analysis
Antineoplastic Agents, Immunological
antineoplastic combined chemotherapy protocols
evaluation of the transparency committee
Malignant Pleural Mesothelioma
Mesothelioma, Malignant
---
https://www.has-sante.fr/jcms/p_3311628/fr/opdivo-nivolumab-cancer-de-l-oesophage-ou-de-la-jonction-oeso-gastrique
https://www.has-sante.fr/jcms/p_3311642/fr/decision-n-2022-0029/dc/sem-du-24-janvier-2022-de-la-presidente-de-la-haute-autorite-de-sante-prise-au-nom-du-college-portant-autorisation-d-acces-precoce-de-la-specialite-opdivo
2022
false
false
false
France
adult
stomach neoplasms
nivolumab
treatment outcome
insurance, health, reimbursement
esophagogastric junction
infusions, intravenous
evaluation of the transparency committee
esophageal neoplasms
esophagogastric junction
Nivolumab
nivolumab
---
https://www.has-sante.fr/jcms/p_3386214/fr/opdivo-nivolumab-cancer-de-l-oesophage
2022
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
infusions, intravenous
Nivolumab
nivolumab
Esophageal Squamous Cell Carcinoma
adult
neoplasm recurrence, local
neoplasm metastasis
Unresectable Esophageal Squamous Cell Carcinoma
Recurrent Esophageal Squamous Cell Carcinoma
Metastatic Esophageal Squamous Cell Carcinoma
PD-L1 Positive
Advanced Esophageal Squamous Cell Carcinoma
Antineoplastic Agents, Immunological
antineoplastic combined chemotherapy protocols
---
https://www.has-sante.fr/jcms/p_3324307/fr/opdivo-nivolumab-cancer-oesophage-ou-jonction-oeso-gastrique
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
stomach neoplasms
residual cancer
infusions, intravenous
Antineoplastic Agents, Immunological
nivolumab
evaluation of the transparency committee
esophagogastric junction
Nivolumab
esophageal neoplasms
---
https://www.has-sante.fr/jcms/p_3272283/fr/opdivo/yervoy-nivolumab/ipilimumab-cancer-bronchique-non-a-petites-cellules-cbnpc
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
Nivolumab
antineoplastic combined chemotherapy protocols
Ipilimumab/Nivolumab Regimen
carcinoma, non-small-cell lung
bronchial neoplasms
neoplasm metastasis
adult
platinum compounds
Antineoplastic Agents, Immunological
evaluation of the transparency committee
Ipilimumab
---
https://www.has-sante.fr/jcms/p_3297501/fr/opdivo-10-mg/ml-nivolumab-carcinome-a-cellules-renales-avance-en-association-cabozantinib
2021
France
evaluation of the transparency committee
carcinoma
Cell
Carcinoma
kidney, nos
Opdivo
"u" lymphocyte
cells
nivolumab
association
carcinoma, renal cell
Nivolumab
cabozantinib
---
https://www.has-sante.fr/jcms/p_3294121/fr/cabometyx-20-40-mg-cabozantinib-carcinome-a-cellules-renales-avance-en-association-au-nivolumab
2021
false
false
false
France
evaluation of the transparency committee
cells
carcinoma
nivolumab
Nivolumab
kidney, nos
"u" lymphocyte
traction
Cell
indication of
carcinoma, renal cell
association
indicators
cabozantinib
Carcinoma
indicators and reagents
---
https://www.has-sante.fr/jcms/p_3285286
2021
false
false
false
France
adult
treatment outcome
infusions, intravenous
nivolumab
Nivolumab
Antineoplastic Agents, Immunological
Esophageal Squamous Cell Carcinoma
Advanced Esophageal Squamous Cell Carcinoma
Metastatic Esophageal Squamous Cell Carcinoma
Recurrent Esophageal Squamous Cell Carcinoma
Unresectable Esophageal Squamous Cell Carcinoma
evaluation of the transparency committee
---
https://ansm.sante.fr/tableau-atu-rtu/opdivo-10-mg-ml-solution-a-diluer-pour-perfusion-2
2021
false
false
false
France
French
infusions, intravenous
guidelines for drug use
continuity of patient care
drug monitoring
adult
melanoma
Antineoplastic Agents, Immunological
Nivolumab
nivolumab
---
https://www.has-sante.fr/jcms/p_3279375/fr/opdivo-nivolumab-/-opdivo-yervoy-nivolumab-ipilimumab
2021
false
false
false
France
French
guidelines for drug use
antineoplastic combined chemotherapy protocols
Nivolumab
Ipilimumab/Nivolumab Regimen
Ipilimumab
Antineoplastic Agents, Immunological
adult
Malignant Pleural Mesothelioma
disease progression
Cancer Progression
infusions, intravenous
Refractory Pleural Malignant Mesothelioma
continuity of patient care
Nivolumab Regimen
nivolumab
ipilimumab
evaluation of the transparency committee
Mesothelioma, Malignant
---
https://www.has-sante.fr/jcms/p_3272292/fr/opdivo-nivolumab-en-monotherapie-tt-adjuvant-de-melanome
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
melanoma
Adjuvant Therapy
Metastatic Melanoma
adult
Lymph Node Involvement
infusions, intravenous
nivolumab
evaluation of the transparency committee
Nivolumab
---
https://www.has-sante.fr/jcms/p_3159912/fr/opdivo
2020
false
false
false
France
nivolumab
antineoplastic agents
insurance, health, reimbursement
treatment outcome
melanoma
neoplasm metastasis
antineoplastic agents
Nivolumab
infusions, intravenous
evaluation of the transparency committee
Nivolumab
---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/choix-de-la-posologie-du-nivolumab-et-du-pembrolizumab.html
2020
Canada
guidelines for drug use
Nivolumab
pembrolizumab
pembrolizumab
nivolumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3290311/fr/opdivo-nivolumab-et-yervoy-ipilimumab-cancer-colorectal-metastatique
2020
false
false
false
France
Ipilimumab/Nivolumab Regimen
evaluation of the transparency committee
ipilimumab
yervoy
Opdivo
Colorectal cancer
nivolumab
colorectal neoplasms
neoplasm, malignant
Ipilimumab
Nivolumab
cancer
malignant neoplasm colon/rectum
---
https://www.has-sante.fr/jcms/p_3297497/fr/opdivo-10-mg/ml-/-yervoy-5-mg/ml-nivolumab-en-association-a-l-ipilimumab-cancer-colorectal-metastatique
2020
false
false
false
France
Ipilimumab/Nivolumab Regimen
evaluation of the transparency committee
indicators and reagents
indicators
cancer
neoplasm, malignant
ipilimumab
yervoy
Colorectal cancer
nivolumab
traction
indication of
association
colorectal neoplasms
Ipilimumab
Opdivo
Nivolumab
malignant neoplasm colon/rectum
---
https://pgtmsite.files.wordpress.com/2024/01/ad-anti-pd-1_final-corr.pdf
2020
false
false
false
Canada
technical report
quebec
pembrolizumab
has patient
Portal vein air
nivolumab
patients
neoplasm, malignant
cancer
Nivolumab
hospitals, university
neoplasms
pembrolizumab
Cancer
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3287835/fr/opdivo-nivolumab-et-yervoy-ipilimumab
2020
false
false
false
France
Ipilimumab/Nivolumab Regimen
evaluation of the transparency committee
yervoy
Opdivo
Ipilimumab
ipilimumab
Nivolumab
nivolumab
---
https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Medicaments/INESSS_Nivolumab_Pembrolizumab_Outil_Posologies-.pdf
2020
Canada
drug evaluation
pembrolizumab
Nivolumab
nivolumab
pembrolizumab
antibodies, monoclonal
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3097610/fr/opdivo-yervoy
2019
false
false
false
France
Nivolumab
carcinoma, renal cell
antineoplastic combined chemotherapy protocols
treatment outcome
adult
antineoplastic agents
Ipilimumab/Nivolumab Regimen
evaluation of the transparency committee
Ipilimumab
---
https://www.has-sante.fr/jcms/p_3067177/fr/opdivo
2019
false
false
false
France
French
evaluation of the transparency committee
Nivolumab
nivolumab
recurrence
hodgkin disease
adult
treatment outcome
Antineoplastic Agents, Immunological
infusions, intravenous
---
https://www.has-sante.fr/jcms/c_2897014/fr/opdivo-nivolumab-anticorps-monoclonal
2019
false
false
false
France
guidelines for drug use
melanoma
treatment outcome
nivolumab
infusions, intravenous
neoplasm metastasis
adult
neoplasm recurrence, local
survival analysis
evaluation of the transparency committee
Nivolumab
---
https://www.has-sante.fr/portail/jcms/c_2896995/en/opdivo
2018
false
false
false
France
antineoplastic agents
infusions, intravenous
nivolumab
evaluation of the transparency committee
antibodies, monoclonal
Nivolumab
---
https://ansm.sante.fr/tableau-marr/nivolumab
2018
false
false
false
France
French
risk management
immune system diseases
nivolumab
Drug-Related side effects and adverse reactions
guidelines for drug use
antineoplastic agents
immune system diseases
Drug-Related side effects and adverse reactions
summary of product characteristics
patient education handout
Drug-Related side effects and adverse reactions
antibodies, monoclonal
Nivolumab
---
https://www.has-sante.fr/portail/jcms/c_2894915/en/opdivo
2018
false
false
false
France
evaluation of the transparency committee
Opdivo
antibodies, monoclonal
Nivolumab
---
https://pgtmsite.files.wordpress.com/2024/01/nivolumab_strategie-posologique.pdf
2018
false
false
false
Canada
technical report
Nivolumab
nivolumab
---
https://www.has-sante.fr/portail/jcms/c_2829034/fr/opdivo
https://www.has-sante.fr/portail/jcms/c_2829034/fr/opdivo-nivolumab-anticorps-anti-pd1
2018
false
false
false
France
French
treatment outcome
evaluation of the transparency committee
infusions, intravenous
nivolumab
antineoplastic agents
antineoplastic agents
adult
carcinoma, squamous cell
upper aerodigestive tract neoplasms
disease progression
Cancer Progression
quality of life
survival analysis
guidelines for drug use
head and neck neoplasms
antibodies, monoclonal
Nivolumab
---
https://www.has-sante.fr/portail/jcms/c_2870207/fr/opdivo
2018
false
false
false
false
France
French
evaluation of the transparency committee
Opdivo
antibodies, monoclonal
Nivolumab
---
https://www.has-sante.fr/portail/jcms/c_2770199/fr/opdivo-melanome-en-association-a-yervoy
https://www.has-sante.fr/portail/jcms/c_2770199/fr/opdivo-nivolumab-anticorps-anti-pd1-melanome-en-association-a-yervoy
2017
false
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
antineoplastic agents
antineoplastic agents
nivolumab
melanoma
Advanced Malignant Neoplasm
neoplasm metastasis
adult
melanoma
infusions, intravenous
BRAF Gene Mutation
programmed cell death 1 receptor
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
disease-free survival
Eastern Cooperative Oncology Group performance status - grade 0 (finding)
Eastern Cooperative Oncology Group performance status - grade 1 (finding)
PDCD1 protein, human
guidelines for drug use
Ipilimumab
Ipilimumab/Nivolumab Regimen
antibodies, monoclonal
antibodies, monoclonal
Nivolumab
Nivolumab
---
http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire&hit=1&r=42015
2017
false
false
false
France
French
legislation
insurance, health, reimbursement
nivolumab
infusions, intravenous
carcinoma, non-small-cell lung
Nonsquamous nonsmall cell neoplasm of lung (disorder)
antineoplastic agents
antibodies, monoclonal
Nivolumab
---
http://www.has-sante.fr/portail/jcms/c_2742286/fr/opdivo-cbnpc-non-epidermoide
2017
false
false
false
false
France
French
treatment outcome
infusions, intravenous
adult
aged
antineoplastic agents
programmed cell death 1 receptor
nivolumab
carcinoma, non-small-cell lung
Locally Advanced Malignant Neoplasm
neoplasm metastasis
evaluation of the transparency committee
survival analysis
Nonsquamous nonsmall cell neoplasm of lung (disorder)
antibodies, monoclonal
antibodies, monoclonal
Nivolumab
Nivolumab
---
http://www.has-sante.fr/portail/jcms/c_2757885/fr/opdivo-lhc
https://www.has-sante.fr/portail/jcms/c_2757885/fr/opdivo-nivolumab-anticorps-anti-pd1
2017
false
false
false
France
French
treatment outcome
infusions, intravenous
adult
antineoplastic agents
programmed cell death 1 receptor
nivolumab
evaluation of the transparency committee
survival analysis
Adult Classic Hodgkin Lymphoma
hodgkin disease
recurrence
Refractory Hodgkin Lymphoma
Recurrent Adult Hodgkin Lymphoma
guidelines for drug use
Autologous Hematopoietic Stem Cell Transplantation
hematopoietic stem cell transplantation
antibodies, monoclonal
antibodies, monoclonal
Nivolumab
Nivolumab
---
http://www.has-sante.fr/portail/jcms/c_2682094/fr/opdivo-carcinome-a-cellules-renales
https://www.has-sante.fr/portail/jcms/c_2682094/fr/opdivo-nivolumab-anticorps-anti-pd1-carcinome-a-cellules-renales
2016
false
false
false
France
French
treatment outcome
infusions, intravenous
adult
antineoplastic agents
programmed cell death 1 receptor
nivolumab
Locally Advanced Malignant Neoplasm
evaluation of the transparency committee
survival analysis
carcinoma, renal cell
clear cell renal cell carcinoma
Clear Cell Neoplasm
guidelines for drug use
antibodies, monoclonal
antibodies, monoclonal
Nivolumab
Nivolumab
---
http://www.conseil-scientifique.public.lu/fr/publications/oncologie/nivolumab.html
2016
false
false
true
Luxembourg
French
guidelines for drug use
nivolumab
Advanced Malignant Neoplasm
melanoma
carcinoma, renal cell
carcinoma, non-small-cell lung
Stage IV Lung Non-Small Cell Cancer AJCC v7
neoplasm metastasis
antineoplastic agents
treatment outcome
survival analysis
infusions, intravenous
programmed cell death 1 receptor
nivolumab
antibodies, monoclonal
Nivolumab
---
https://www.has-sante.fr/portail/jcms/c_2612055/fr/opdivo-nivolumab-anticorps-anti-pd1
http://www.has-sante.fr/portail/jcms/c_2612055/fr/opdivo-nivolumab-anticorps-anti-pd1
2016
false
false
false
France
French
treatment outcome
infusions, intravenous
adult
aged
antineoplastic agents
programmed cell death 1 receptor
nivolumab
carcinoma, non-small-cell lung
Locally Advanced Malignant Neoplasm
neoplasm metastasis
evaluation of the transparency committee
squamous cell cancer
guidelines for drug use
survival analysis
antibodies, monoclonal
antibodies, monoclonal
neoplasms, squamous cell
Nivolumab
Nivolumab
---
http://www.has-sante.fr/portail/jcms/c_2639665/fr/opdivo-nivolumab-anticorps-anti-pd1
2016
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
antineoplastic agents
antineoplastic agents
nivolumab
guidelines for drug use
melanoma
Advanced Malignant Neoplasm
neoplasm metastasis
adult
melanoma
infusions, intravenous
BRAF Gene Mutation
programmed cell death 1 receptor
antibodies, monoclonal
antibodies, monoclonal
Nivolumab
Nivolumab
---
https://www.ema.europa.eu/medicines/human/EPAR/Opdivo
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
product surveillance, postmarketing
drug monitoring
infusions, intravenous
melanoma
neoplasm metastasis
Unresectable Malignant Neoplasm
adult
aged
antineoplastic agents
antineoplastic agents
drug interactions
pregnancy
breast feeding
programmed cell death 1 receptor
drug evaluation, preclinical
drug compounding
Metastatic Melanoma
nivolumab
carcinoma, non-small-cell lung
carcinoma, renal cell
hodgkin disease
head and neck neoplasms
Head and Neck Squamous Cell Carcinoma
Urothelial Carcinoma
Malignant Pleural Mesothelioma
colorectal neoplasms
Microsatellite instability-high colorectal cancer (disorder)
Esophageal Squamous Cell Carcinoma
Gastroesophageal junction cancer
esophageal neoplasms
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
adenocarcinoma of esophagus
antibodies, monoclonal
antibodies, monoclonal
Nivolumab
Nivolumab
---
https://www.ema.europa.eu/medicines/human/EPAR/nivolumab-bms
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
product surveillance, postmarketing
drug monitoring
infusions, intravenous
Advanced Malignant Neoplasm
adult
aged
antineoplastic agents
antineoplastic agents
drug interactions
pregnancy
breast feeding
programmed cell death 1 receptor
drug evaluation, preclinical
drug compounding
carcinoma, non-small-cell lung
nivolumab
antibodies, monoclonal
antibodies, monoclonal
Nivolumab
Nivolumab
---